Gretchen M Brophy

Summary

Affiliation: Virginia Commonwealth University
Country: USA

Publications

  1. doi Emergency Neurological Life Support: Pharmacotherapy
    Gretchen M Brophy
    Departments of Pharmacotherapy and Outcomes Science and Neurosurgery, Virginia Commonwealth University, Richmond, VA, USA
    Neurocrit Care 23:S48-68. 2015
  2. pmc Exposure of cyclosporin A in whole blood, cerebral spinal fluid, and brain extracellular fluid dialysate in adults with traumatic brain injury
    Gretchen M Brophy
    Department of Pharmacotherapy and Outcomes Science, Medical College of Virginia Campus, Richmond, Virginia 23298 0533, USA
    J Neurotrauma 30:1484-9. 2013
  3. doi Guidelines for the evaluation and management of status epilepticus
    Gretchen M Brophy
    Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Medical College of Virginia Campus, 410 N 12th Street, P O Box 980533, Richmond, VA 23298 0533, USA
    Neurocrit Care 17:3-23. 2012
  4. pmc Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids
    Gretchen M Brophy
    Virginia Commonwealth University, Pharmacotherapy and Outcomes Sciences and Neurosurgery, Richmond, Virginia 23298 0533, USA
    J Neurotrauma 28:861-70. 2011
  5. doi Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients
    Gretchen M Brophy
    Departments of Pharmacotherapy and Outcomes Sciences and Neurosurgery, Virginia Commonwealth University School of Pharmacy, P O Box 980533, 410 N 12th Street, Richmond, VA 23298, USA
    Neurocrit Care 13:176-81. 2010
  6. pmc alphaII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury
    Gretchen M Brophy
    Departments of Pharmacy and Neurosurgery, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, Virginia 23298 0533, USA
    J Neurotrauma 26:471-9. 2009
  7. doi A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit
    Gretchen M Brophy
    Departments of Pharmacy and Neurosurgery, Virginia Commonwealth University, Richmond, Virginia 23298 0533, USA
    Clin Ther 30:2324-34. 2008
  8. ncbi Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness
    Stacy A Voils
    School of Pharmacy, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, Virginia 23298 0533, USA
    Pharmacotherapy 27:535-41. 2007
  9. doi Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events
    Gretchen M Brophy
    Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA, USA
    Ann Pharmacother 47:447-54. 2013
  10. ncbi The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients
    Curtis N Sessler
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Virginia Commonwealth University Health System, Richmond, Virginia 23298, USA
    Am J Respir Crit Care Med 166:1338-44. 2002

Detail Information

Publications13

  1. doi Emergency Neurological Life Support: Pharmacotherapy
    Gretchen M Brophy
    Departments of Pharmacotherapy and Outcomes Science and Neurosurgery, Virginia Commonwealth University, Richmond, VA, USA
    Neurocrit Care 23:S48-68. 2015
    ....
  2. pmc Exposure of cyclosporin A in whole blood, cerebral spinal fluid, and brain extracellular fluid dialysate in adults with traumatic brain injury
    Gretchen M Brophy
    Department of Pharmacotherapy and Outcomes Science, Medical College of Virginia Campus, Richmond, Virginia 23298 0533, USA
    J Neurotrauma 30:1484-9. 2013
    ..These exposure characteristics should be used for safer CsA dose optimization to achieve target CsA concentrations for neuroprotection in future TBI studies...
  3. doi Guidelines for the evaluation and management of status epilepticus
    Gretchen M Brophy
    Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Medical College of Virginia Campus, 410 N 12th Street, P O Box 980533, Richmond, VA 23298 0533, USA
    Neurocrit Care 17:3-23. 2012
    ....
  4. pmc Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids
    Gretchen M Brophy
    Virginia Commonwealth University, Pharmacotherapy and Outcomes Sciences and Neurosurgery, Richmond, Virginia 23298 0533, USA
    J Neurotrauma 28:861-70. 2011
    ..This study shows a significant correlation between UCH-L1 CSF and serum median concentrations and biokinetics in severe TBI patients, and relationships with clinical outcome were detected...
  5. doi Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients
    Gretchen M Brophy
    Departments of Pharmacotherapy and Outcomes Sciences and Neurosurgery, Virginia Commonwealth University School of Pharmacy, P O Box 980533, 410 N 12th Street, Richmond, VA 23298, USA
    Neurocrit Care 13:176-81. 2010
    ..There is a paucity of studies comparing stress ulcer prophylaxis (SUP) agents in high-risk neurosurgical patients...
  6. pmc alphaII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury
    Gretchen M Brophy
    Departments of Pharmacy and Neurosurgery, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, Virginia 23298 0533, USA
    J Neurotrauma 26:471-9. 2009
    ..Further studies are being conducted to determine if exposure and kinetic metrics for biofluid-based biomarkers can predict clinical outcome...
  7. doi A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit
    Gretchen M Brophy
    Departments of Pharmacy and Neurosurgery, Virginia Commonwealth University, Richmond, Virginia 23298 0533, USA
    Clin Ther 30:2324-34. 2008
    ..Darbepoietin alfa and epoetin alfa are erythropoiesis-stimulating agents (ESAs) used to manage anemia in the ICU, although neither drug has an indication in critically ill patients...
  8. ncbi Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness
    Stacy A Voils
    School of Pharmacy, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, Virginia 23298 0533, USA
    Pharmacotherapy 27:535-41. 2007
    ..To compare the effectiveness of darbepoetin alfa with epoetin alfa (recombinant human erythropoietin [rHuEPO]) for achieving transfusion independence and increasing hemoglobin concentrations in critically ill patients...
  9. doi Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events
    Gretchen M Brophy
    Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA, USA
    Ann Pharmacother 47:447-54. 2013
    ..Recombinant activated factor VII (rFVIIa) is frequently used in these situations to control bleeding; however, few controlled clinical trials have demonstrated clinical benefit and prolonged survival...
  10. ncbi The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients
    Curtis N Sessler
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Virginia Commonwealth University Health System, Richmond, Virginia 23298, USA
    Am J Respir Crit Care Med 166:1338-44. 2002
    ..Our nurses described RASS as logical, easy to administer, and readily recalled. RASS has high reliability and validity in medical and surgical, ventilated and nonventilated, and sedated and nonsedated adult ICU patients...
  11. doi Perceived versus actual sedation practices in adult intensive care unit patients receiving mechanical ventilation
    Kimberly Varney Gill
    Virginia Commonwealth University Health System, Department of Pharmacy, Department of Pulmonary and Critical Care Medicine, Richmond, USA
    Ann Pharmacother 46:1331-9. 2012
    ..With drug shortages, newer sedative medications, and updates in research, management of sedation and delirium in patients receiving mechanical ventilation continues to evolve...
  12. doi Safety of imipenem/cilastatin in neurocritical care patients
    Jason Hoffman
    Department of Pharmacy, Carilion Roanoke Memorial Hospital, Roanoke, VA, USA
    Neurocrit Care 10:403-7. 2009
    ..We sought to evaluate the safety of imipenem/cilastatin in the treatment of infections, including meningitis, in neurocritical care patients...